

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

**GENERIC PHARMACEUTICAL INDUSTRY ASSN**

2. Address:

2300 CLARENDON BOULEVARD Suite 400, ARLINGTON, VA 22201

3. Principal place of business (if different from line 2):

4. Contact Name: JASON MONEY

Telephone: 7036472480

E-mail (optional): jmoney@gphaonline.org

Senate ID #: 16032-12

House ID #:

7. Client Name:  Self

## TYPE OF REPORT

8. Year 2007 Midyear (January 1 - June 30):  **OR** Year End (July 1 - December 31):

9. Check if this filing amends a previously filed version of this report:

10. Check if this is a Termination Report:  => Termination Date: \_\_\_\_\_ 11. No Lobbying Activity:

## INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

### 12. Lobbying Firms

**INCOME** relating to lobbying activities for this reporting period was:

Less than \$10,000:

\$10,000 or more:  => Income (nearest \$20,000): \_\_\_\_\_

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

### 13. Organizations

**EXPENSES** relating to lobbying activities for this reporting period were:

Less than \$10,000:

\$10,000 or more:  => Expenses (nearest \$20,000): 420,000.00

### 14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

- Method A.** Reporting amounts using LDA definitions only  
 **Method B.** Reporting amounts under section 6033(b)(8) of the Internal Revenue Code  
 **Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code

Registrant Name: GENERIC PHARMACEUTICAL INDUSTRY ASSN Client Name: Self

### LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: BUD (one per page)

16. Specific lobbying issues:

Office of Generic Drugs Appropriations - S.1859 and H.R. 3161

17. House(s) of Congress and Federal agencies contacted:

Food & Drug Administration (FDA)  
HOUSE OF REPRESENTATIVES  
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: HEIMBERG, GARY

Covered Official Position (if applicable): N/A

Name: JAEGER, KATHLEEN D.

Covered Official Position (if applicable): N/A

Name: MONEY, JASON

Covered Official Position (if applicable): N/A

Name: O'CONNOR, REILLY

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: GENERIC PHARMACEUTICAL INDUSTRY ASSN Client Name: Self

### LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: CPT (one per page)

16. Specific lobbying issues:

Patent Reform - S.1195 and H.R.1908 Patent Settlements - S.316, H.R.1432 and H.R. 1902

17. House(s) of Congress and Federal agencies contacted:

Congressional Budget Office (CBO)  
HOUSE OF REPRESENTATIVES  
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: HEIMBERG, GARY

Covered Official Position (if applicable): N/A

Name: JAEGER, KATHLEEN D.

Covered Official Position (if applicable): N/A

Name: MONEY, JASON

Covered Official Position (if applicable): N/A

Name: O'CONNOR, REILLY

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: GENERIC PHARMACEUTICAL INDUSTRY ASSN Client Name: Self

### LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MMM (one per page)

16. Specific lobbying issues:

Medicaid Reimbursement - S.1951 and H.R.3140 S-Chip/Rebates - S.1893 and H.R. 3162

17. House(s) of Congress and Federal agencies contacted:

Centers For Medicare and Medicaid Services (CMS)

HOUSE OF REPRESENTATIVES

Health & Human Services, Dept of (HHS)

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: HEIMBERG, GARY

Covered Official Position (if applicable): N/A

Name: JAEGER, KATHLEEN D.

Covered Official Position (if applicable): N/A

Name: LOTT, BRUCE

Covered Official Position (if applicable): N/A

Name: MONEY, JASON

Covered Official Position (if applicable): N/A

Name: O'CONNOR, REILLY

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: GENERIC PHARMACEUTICAL INDUSTRY ASSN Client Name: Self

### LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: PHA (one per page)

16. Specific lobbying issues:

Generic Biologics - S.623, S.1695, H.R. 1038, and H.R. 1956  
S.484 and S.1082  
and S.25 Counterfeit Drugs - S.242, S.1082, H.R. 780 and H.R.2710  
Pediatric Exclusivity - S.1082 and H.R. 2900 Drug Safety -  
Authorized Generics - S.438 and H.R. 806 Citizen Petitions - S.1088

17. House(s) of Congress and Federal agencies contacted:

Congressional Budget Office (CBO)  
Food & Drug Administration (FDA)  
HOUSE OF REPRESENTATIVES  
Health & Human Services, Dept of (HHS)  
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: HEIMBERG, GARY  
Covered Official Position (if applicable): N/A  
Name: JAEGER, KATHLEEN D.  
Covered Official Position (if applicable): N/A  
Name: LOTT, BRUCE  
Covered Official Position (if applicable): N/A  
Name: MONEY, JASON  
Covered Official Position (if applicable): N/A  
Name: O'CONNOR, REILLY  
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: GENERIC PHARMACEUTICAL INDUSTRY ASSN Client Name: Self

### LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: TRD (one per page)

16. Specific lobbying issues:

Korea Free Trade Agreement Panama Free Trade Agreement Peru Free Trade Agreement Columbia Free Trade Agreement

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

U.S. Trade Representative (USTR)

18. Name of each individual who acted as a lobbyist in this issue area:

Name: HEIMBERG, GARY

Covered Official Position (if applicable): N/A

Name: JAEGER, KATHLEEN D.

Covered Official Position (if applicable): N/A

Name: MONEY, JASON

Covered Official Position (if applicable): N/A

Name: O'CONNOR, REILLY

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Signature: ON FILE Date: Aug 13, 2007

Printed Name and Title: KATHLEEN JAEGER - PRESIDENT AND CEO -

**Information Update Page:**

**Complete ONLY where registration information has changed.**

**LOBBYIST UPDATE**

**23. Name of each previously reported individual who is NO LONGER expected to act as a lobbyist for the client**

**ISSUE UPDATE**

**24. General lobbying issues previously reported that NO LONGER pertain**

**AFFILIATED ORGANIZATIONS**

**25. Add the following organization(s)**

**26. Name of each previously reported organization that is NO LONGER affiliated with the registrant or client**

**FOREIGN ENTITIES**

**27. Add the following foreign entities**

**28. Name of each previously reported foreign entity the NO LONGER owns, OR controls, OR is affiliated with the registrant, client or affiliated organization**

Signature: ON FILE      Date: Aug 13, 2007

Printed Name and Title: -